2033eP Exploring diversity in patient and caregiver treatment preferences for tyrosine kinase inhibitors (TKIs) in stage 4 ALK+ non-small cell lung cancer (NSCLC). - Culver, K.W.; Seo, J.; Trapali, M.; Clarke, H.; Whitty, J.; Sethi, A.; Cherepanov, D.; Farmen, S.; Danes, C.G. (Annals of Oncology, 2025)